|
2. ETIOLOGIE
|
|
|
|
3.5 PRÉVENTION - UV
|
|
|
|
4. DÉPISTAGE, DIAGNOSTIC ET PRONOSTIC
|
|
|
|
|
4.10 DÉP., DIAG. & PRONO. - FDA, EMA, NICE,...
|
|
|
|
4.12 BIOPSIES LIQUIDES
|
|
|
|
5.12.5 IMMUNOTHÉRAPIES - PHARMA
|
|
|
|
5.12.8 IMMUNOTHÉRAPIES - ECONOMIE
|
|
|
Dynavax axes immuno-oncology pipeline and 82 staff [Fierce Biotech]
|
|
|
|
|
|
Work is underway to wind down the immuno-oncology trials. Dynavax is the sponsor of a phase 1/2 trial that is testing SD-101 in combination with Merck’s Keytruda. And the same drug is being tested in a clutch of trials sponsored by other groups, including QuantumLeap Healthcare Collaborative’s I-SPY 2 trial.
|
|
|
|
|
|
|
|
|
5.2 PHARMA
|
|
|
|
|
5.2.3 PHARMA - ÉCONOMIE
|
|
|
|
|
5.3.4 TRAITEMENTS - AMM (FDA, EMA,...)
|
|
|
|
|
FDA approves first PI3K inhibitor for breast cancer [FDA]
|
|
|
|
|
|
Today, the U.S. Food and Drug Administration approved Piqray (alpelisib) tablets, to be used in combination with the FDA-approved endocrine therapy fulvestrant, to treat postmenopausal women, and men, with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, PIK3CA-mutated, advanced or metastatic breast cancer (as detected by an FDA-approved test) following progression on or after an endocrine-based regimen.
|
|
|
|
|
|
|
|
|
5.4 TRAITEMENTS - ECONOMIE
|
|
|
|
|
6.11 PATIENTS
|
|
|
|
6.4 MÉDICO-ÉCO
|
|
|
|
6.9 CONTROVERSES
|
|
|